Clinical trials: Immunologic Deficiency Syndrome
HIV, HIV Infections
HIV Persistence and Viral Reservoirs
Although highly active antiretroviral therapy (HAART) decreases HIV-associated mortality, it does not to completely restore health.
- Trial name
- NCT01025427
- Testing
- Raltegravir, tenofovir/emtricitabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
HIV Infections
Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx
This study will examine whether interleukin-2 (IL-2) given before the interruption of antiretroviral (ARV) treatment could significantly extend the period of time that a patient is temporarily not taking ARV treatment and also…
- Trial name
- ILIADE (NCT00071890)
- Testing
- Interleukin 2, HAART, Treatment interruption
- Where
- 2 sites in United States, France
- Volunteers
- 148 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in vitro activity against HIV-1 strains including those resistant to currently available antiretroviral drugs.
- Trial name
- NCT00515827
- Testing
- Raltegravir (MK-0518)
- Where
- 20 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anal Cancer, Nonneoplastic Condition
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection.
- Conditions
- Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
- Trial name
- NCT01209325
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, laboratory biomarker analysis
- Where
- 19 sites in United States, Puerto Rico
- Volunteers
- 149 people
- Sponsor
- AIDS Malignancy Consortium
Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND)
A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV
HIV related cognitive impairment still occurs despite highly active antiretroviral therapy (HAART). HIV disease affects the brain in 20-40% of patients with advancing HIV disease leading to varying degrees of cognitive…
- Trial name
- HANDral (NCT01448486)
- Testing
- Raltegravir
- Where
- 2 sites in Australia
- Volunteers
- 6 people
- Sponsor
- St Vincent's Hospital, Sydney
HIV Infections, Sexually Transmitted Infections
Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women
The purpose of this program evaluation is to determine whether the Health Love Workshop, a group-level HIV behavioral intervention, reduces HIV-related sex risk behaviors and increases HIV protective behaviors of African American…
- Trial name
- NCT00362375
- Testing
- Healthy Love Workshop, HIV/AIDS 101 Workshop
- Where
- United States
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Substance-Related Disorders, Mental Disorder
Community Health Worker Training to Reduce Depression and Substance Use Stigma in TB/HIV Care in South Africa
Poor engagement in care contributes to HIV- and TB-related morbidity and mortality in South Africa (SA). Community health workers (CHWs) are frontline lay health workers who work to re-engage patients who are lost to follow-up…
- Conditions
- Substance-Related Disorders, Mental Disorder, Social Stigma, Depression
- Trial name
- Siyakhana (NCT05282173)
- Testing
- Siyakhana CHW Training
- Where
- South Africa
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of Maryland, College Park
Human Immunodeficiency Virus
Drug Use Investigation of Kaletra
This non-interventional, post-marketing observational study was conducted to obtain data, such as safety and effectiveness, from the use of lopinavir/ritonavir (Kaletra) in clinical practice and investigate the necessity to…
- Trial name
- NCT01076972
- Testing
- Lopinavir/ritonavir (Kaletra)
- Where
- 29 sites in Japan
- Volunteers
- 1,184 people
- Sponsor
- Abbott
HIV Infections
Clinical Trial of CNS-targeted HAART (CIT2)
CIT2 is a strategy for targeting HAART (Highly Active Antiretroviral Therapy) to the CNS (Central Nervous System) in patients with HIV associated neurocognitive impairment (HNCI).
- Trial name
- NCT00624195
- Testing
- FDA Approved Antiretroviral Therapy (see list below)
- Where
- 5 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of California, San Diego
HIV Infections
Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV
A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been shown to be an effective way of reducing the risk of mother-to-child transmission (MTCT) of HIV.
- Trial name
- P1060 (NCT00307151)
- Testing
- Lamivudine, Lopinavir/ritonavir, Nevirapine
- Where
- 10 sites in India, Malawi and 5 more
- Volunteers
- 452 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
HIV Infections
A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
The hypothesis tested in this study is that doravirine (MK-1439) at the final dose selected is superior to efavirenz, each given in combination with TRUVADA®, as measured by the percentage of participants with CNS events by Week…
- Trial name
- NCT01632345
- Testing
- Doravirine, Efavirenz, TRUVADA®
- Volunteers
- 342 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, Lipodystrophy
Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs) are a class of anti-HIV (Human Immunodeficiency Virus) drug that can be an important part of an HIV treatment regimen.
- Conditions
- HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
- Trial name
- NCT00119405
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ataxia Telangiectasia
Evaluate the Neurological Effects of EryDex on Subjects With A-T
This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate [DSP] in autologous erythrocytes)…
- Trial name
- NEAT (NCT06193200)
- Testing
- Dexamethasone sodium phosphate
- Where
- 19 sites in United States, Denmark and 7 more
- Volunteers
- 105 people
- Sponsor
- Quince Therapeutics S.p.A.
HIV/AIDS, Alcohol Abuse
An Economic and Relationship-strengthening Intervention for HIV-affected Couples Who Drink Alcohol in Malawi
A couples-based alcohol-reduction and economic and relationship-strengthening intervention for HIV-affected couples in Malawi.
- Trial name
- NCT04906616
- Testing
- Mlambe
- Where
- Malawi
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Acute HIV Infection, HIV Infections
Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
This is a pilot study of treatment of acute HIV infection with a once daily regimen of Emtricitabine, Tenofovir and Efavirenz. The primary objectives of this study are: 1.
- Trial name
- NCT00924898
- Testing
- efavirenz, emtricitabine, and tenofovir
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r
For participants with HIV taking either lopinavir or fosamprenavir who have elevated triglycerides, this trial will study the change in triglycerides after switching protease inhibitors.
- Trial name
- LARD (NCT00756730)
- Testing
- ATV/r, DRV/r
- Where
- 11 sites in United States
- Volunteers
- 49 people
- Sponsor
- Community Research Initiative of New England
HIV-1
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
The purpose of this study is to evaluate the pharmacokinetics, safety and antiviral activity of rilpivirine (TMC278) 25 milligram (mg) or adjusted dose once daily in combination with an investigator-selected background regimen…
- Trial name
- NCT00799864
- Testing
- Rilpivirine, Zidovudine, Abacavir
- Where
- 17 sites in United States, India and 6 more
- Volunteers
- 54 people
- Sponsor
- Janssen Sciences Ireland UC
Alcohol; Harmful Use, Binge Drinking
Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women
African American (AA) women are disproportionately affected by HIV/AIDs. The major risk factor for HIV acquisition among AA women is high-risk heterosexual sex, including unprotected vaginal and anal sex, and sex with a high-risk…
- Conditions
- Alcohol; Harmful Use, Binge Drinking, Risk Behavior, HIV Infection
- Trial name
- NCT01125371
- Testing
- Computerized brief alcohol intervention + IVR booster calls, Computerized brief alcohol intervention, Attention Control
- Where
- United States
- Volunteers
- 439 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV Infections
The Safety and Immunogenicity of a Potential HIV Vaccine
The potential HIV vaccine has two components: a protein immunogen based on the coat protein of HIV; and an adjuvant which enhances the vaccinee's response to the immunogen.
- Trial name
- NCT01966900
- Testing
- CN54gp140 mixed with GLA-AF
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Primary Immunodeficiency
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
This multicenter, open-label, parallel-arm, non-randomized study is designed to evaluate safety and tolerability of higher infusion parameters of IgPro20 in subjects with primary immunodeficiency (PID).
- Trial name
- NCT03033745
- Testing
- IgPro20
- Where
- 12 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- CSL Behring
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.